Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
0.5850
+0.0006 (0.10%)
At close: Sep 12, 2025, 4:00 PM EDT
0.5999
+0.0149 (2.55%)
After-hours: Sep 12, 2025, 7:34 PM EDT
Lifeward Revenue
Lifeward had revenue of $5.72M in the quarter ending June 30, 2025, a decrease of -14.66%. This brings the company's revenue in the last twelve months to $24.43M, up 4.96% year-over-year. In the year 2024, Lifeward had annual revenue of $25.66M with 85.24% growth.
Revenue (ttm)
$24.43M
Revenue Growth
+4.96%
P/S Ratio
0.24
Revenue / Employee
$305,388
Employees
80
Market Cap
9.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.66M | 11.81M | 85.24% |
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LFWD News
- 5 days ago - First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 6 days ago - Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 4 weeks ago - Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Lifeward Ltd. Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership - GlobeNewsWire
- 5 weeks ago - Lifeward to Report Second Quarter Financial Results on August 14, 2025 - GlobeNewsWire
- 5 weeks ago - Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region - GlobeNewsWire
- 2 months ago - MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion - PRNewsWire